Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine

Human Gene Therapy

Volumn 11, Issue 5, 2000, Pages 681-692

  Hsieh, Chia Ling ^a   Chen, Ding Shinn ^b   Hwang, Lih Hwa ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE DEFICIENCY; MALE; MOUSE; MURINE LEUKEMIA; NONHUMAN; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CULTURE MEDIA, CONDITIONED; CYTOKINES; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERLEUKIN-10; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MURINAE;

EID: 0034689206     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015581     Document Type: Article

References (45)

1. Armstrong, C.A., Botella, R., Galloway, T.H., Murray, N., Kramp, J.M., Song, I.S., and Ansel, J.C. (1996). Anti-tumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 56, 2191-2198.
2. Beissert, S., Hosoi, J., Grabbe, S., Asahina, A., and Granstein, R.D. (1995). IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol. 154, 1280-1286.
3. Blankenstein, T. (1994). Increasing tumor immunogeneicity by genetic modification. Br. J. Cancer 70, 1182-1187.
4. Blankenstein, T., Rowley, D., and Schreiber, H. (1991). Cytokines and cancer: Experimental systems. Curr. Opin. Immunol. 3, 694-698.
5. Bomstein, Y., Ophir, R., Harshemes, H., and Ben-Efraim, S. (1993). Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: A possible mechanism of defense. Anticancer Res. 13, 2125-2129.
6. Boon, T., and Van Der Bruggen, P. (1996). Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
7. Bromberg, J.S. (1995). IL-10 immunosuppression in transplantation. Curr. Opin. Immunol. 7, 639-643.
8. Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
9. Colombo, M.P., and Forni, G. (1994). Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol. Today 15, 48-51.
10. De Waal-Malefyt, R., Haanen, J., Spits, H., Roncarolo, M.-G., Te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., and De Vries, J.E. (1991). Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174, 915-924.
11. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackason, V., Hamada, H., Pardoll, D., and Mulligan, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
12. Enk, A.H., Angeloni, V.L., Udey, M.C., and Katz, S.I. (1993). Inhibition of Langerhans cells antigen-presenting function by IL-10: A role for IL-10 in induction of tolerance. J. Immunol. 151, 2390-2398.
13. Fiorentino, D.F., Zlotnik, A., Mosmann, T.R., Howard, M., and O'Garra, A. (1991a). IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815-3822.
14. Fiorentino, D.F., Zlotnik, A., Vieira, P., Morsmann, T.R., Howard, M., Moore, K.W., and O'Garra, A. (1991b). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146, 3444-3451.
15. Fitzpatrick, L., Makrigiannis, A.P., Kaiser, M., and Hoskin, D.W. (1996). Anti-CD3-activated killer T cells: Interferon-γ and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity. J. Interferon Cytokine Res. 16, 537-546.
16. Gerard, C.M., Bruyns, C., Delvaux, A., Baudson, N., Dargent, J.-L., Goldman, M., and Velu, T. (1996). Loss of tumorigenecity and increased immunogenecity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum. Gene Ther. 7, 23-31.
17. Giovarelli, M., Musiani, P., Modesti, A., Dellabona, P., Casorati, G., Allione, A., Consalvo, M., Cavallo, F., De Pierro, F., De Giovanni, C., Musso, T., and Forni, G. (1995). Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances anti-tumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. 155, 3112-3123.
18. + T and NK cells. J. Exp. Med. 180, 1937-1942.
19. + T cells. J. Exp. Med. 184, 19-29.
20. + T cells. J. Immunol. 160, 3188-3193.
21. Halak, B.K., Maguire, H.C., Jr., and Lattime, E.C. (1999). Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 59, 911-917.
22. Hsieh, C.L., Chen, B.F., Wang, C.C., Liu, H.H., Chen, D.S., and Hwang, L.H. (1995). Improved gene expression by a modified bicistronic retroviral vector. Biochem. Biophys. Res. Commun. 214, 910-917.
23. Hsieh, C.L., Pang, V.F., Chen, D.S., and Hwang, L.H. (1997). Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: Implications for cytotoxic T lymphocyte responses and tumor burdens. Hum. Gene Ther. 8, 1843-1854.
24. Jaffee, E.M., and Pardoll, D.M. (1996). Murine tumor antigens: Is it worth the search? Curr. Opin. Immunol. 8, 622-627.
25. Julius, M.H., Simpson, E., and Herzenberg, L.A. (1973). A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur. J. Immunol. 3, 645-659.
26. Kern, D., Klarnet, J., Jenson, M., and Greenberg, P. (1986). Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol. 136, 4303-4310.
27. Kundu, N., Beaty, T.L., Jackson, M.J., and Fulton, A.M. (1996). Antimetastatic and anti-tumor activities of interleukin-10 in a murine model of breast cancer. J. Natl. Cancer Inst. 88, 536-541.
28. Kuppner, M.C., Sawamura, Y., Hamou, M.-F., and De Tribolet, N. (1990). Influence of PGE2-and cAMP-modulating agents on human glioblastoma cells killing by interleukin-2-activated lymphocytes. J. Neurosurg. 72, 619-625.
29. Matsuda, M., Salazar, F., Pertersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q.J., Masucci, M.G., and Kiessling, R. (1994). Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and down-regulates HLA class I expression. J. Exp. Med. 180, 2371-2376.
30. Maxwell, M., Galanopoulos, T., Neville-Golden, J., and Antoniades, H.N. (1992). Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 76, 799-804.
31. Nakayama, E., Shiku, H., Takahashi, T., Oettgen, H.F., and Old, L.J. (1979). Definition of a unique cell line surface antigen of mouse leukemia RL ♂ 1 by cell mediated cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 76, 3486-3490.
32. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and Nakayama, E. (1999). Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128-3133.
33. Pardoll, D. (1992). New strategies for active immunotherapy with genetically engineered tumor cells. Curr. Opin. Immunol. 4, 619-632.
34. Pardoll, D. (1993). Cancer vaccines. Immunol. Today 14, 310-316.
35. Qin, A., Noffz, G., Mohaupt, M., and Blankenstein, T. (1997). Interleukin-10 prevents dendritic cells accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159, 770-776.
36. + T cell clones inhibit anti-tumor T cell function by secreting IL-10. J. Immunol. 155, 5719-5727.
37. Rook, A.H., Kehrl, J.H., Wakefield, L.M., Roberts, A.B., Sporn, M.B., Burlington, D.B., Lane, H.C., and Fauci, A.S. (1986). Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136, 3916-3920.
38. Saito, S., Bannerji, R., Gansbacher, B., Rosenthal, F.M., Romanenko, P., Heston, W.D.W., Fair, W.R., and Gilboa, E. (1994). Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54, 3516-3520.
39. Taga, K.G., and Tosato, G. (1992). IL-10 inhibits T cell proliferation and IL-2 production. J. Immunol. 148, 1143-1148.
40. Takeuchi, T., Ueki, T., Sasaki, Y., Kajiwara, T., Li, B., Moriyama, N., and Kawabe, K. (1997). Th2-like response and anti-tumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol. Immunother. 43, 375-381.
41. Torre-Amione, G., Beauchamp, R.D., Koeppen, H., Park, B.H., Schreiber, H., Moses, H.L., and Rowley, D.A. (1990). A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. U.S.A. 87, 1486-1490.
42. Tseng, S.H., Hwang, L.H., and Lin, S.M. (1997). Induction of anti-tumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J. Immunother. 20, 334-342.
43. Uenaka, A., Ono, T., Akisawa, T., Wada, H., Yasuda, T., and Nakayama, E. (1994). Identification of a unique antigen peptide pRL1 on BALB/c RL ♂ 1 leukemia recognized by cytotoxic T lymphocytes and its relation of the akt oncogene. J. Exp. Med. 180, 1599-1607.
44. Wakefield, L.M., Winokur, T.S., Holland, R.S., Christopherson, K., Levinson, A.D., and Sporn, M.B. (1991). Recombinant latent transforming growth factor β1 has a longer plasma half-life in rats than active transforming growth factor β1, and a different tissue distribution. J. Clin. Invest. 86, 1976-1984.
45. Willems, F., Marchant, A., Delville, J.A., Gerard, C., Delvaux, A., Velu, T., De Boer, M., and Goldman, M. (1994). Interleukin-10 inhibits B7 and intercellular molecule-1 expression on human monocytes. Eur. J. Immunol. 24, 1007-1009.